MDY Healthcare Ltd
Creating energy from natural, managed resources
UK Government Access Keys System
Grahame CookNon-executive Chairman
Grahame Cook was appointed to the board in May 2010. Grahame is a chartered accountant and has more than 20 years' experience in investment banking in London, Switzerland and Germany. He was a director at Barclays de Zoete Wedd until 1995, then a Managing Director at UBS Investment Banking until 1998 following which he was CEO of West LB Panmure until 2003.
Grahame has significant experience of capital raising, capital structuring and mergers and acquisitions. Since 2003, he has been a non-executive director of a number of companies, including Minoan Group plc, a resort developer, and Antisoma plc, a biotech company. Grahame is the chairman of Sinclair Pharma plc, a skin and mouth disease specialist.
Martin HuntNon-executive Deputy Chairman
Martin Hunt was appointed to the board in May 2010. Martin has spent 28 years in the medtech industry working for both multi-nationals and small to medium size enterprises. He spent 10 years at American Cyanamid in sales and marketing positions in the fields of pharmaceuticals, wound closure and latterly, ophthalmic surgery as marketing director for Europe, Middle East & Africa. Martin spent five years at Bristol-Myers Squibb in wound care and stoma therapy as Regional Operations Director and then VP Sales, Europe between 1994 and 1996.
Martin was a founder of a start-up in the IV infusion field before joining Tissue Science (TSL), a company with a novel collagen-based technology, as CEO in 1999. Under Martin's leadership, TSL was successfully admitted to AIM in 2001 and then sold to Covidien in 2008 at a substantial premium to the share price reflecting significant growth in revenues at TSL. Since leaving TSL, Martin has continued to be involved in medtech innovations with a number of non-executive director and advisor roles. These include Orthox Limited, an Oxford spin-out in the field of cartilage repair where he is chairman; Director and advisor at Trophos SA, a French biotech addressing CNS diseases; Programme Director at i4i (a National Institute for Health Research early stage medtech funding programme) and a Venture Partner at H2O Venture Partners in Oxford.